Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04114136
Title	Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Dan Zandberg
Indications	renal cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma lung non-small cell carcinoma melanoma gastric adenocarcinoma Advanced Solid Tumor transitional cell carcinoma hepatocellular carcinoma
Therapies	Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UPMC Hillman Cancer Center	RECRUITING	Pittsburgh	Pennsylvania	15232	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field